Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,630 Million (Small Cap)
20.00
NA
3.07%
-0.67
13.30%
3.03
Revenue and Profits:
Net Sales:
273 Million
(Quarterly Results - Sep 2025)
Net Profit:
36 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.44%
0%
1.44%
6 Months
-16.2%
0%
-16.2%
1 Year
14.87%
0%
14.87%
2 Years
52.85%
0%
52.85%
3 Years
-26.61%
0%
-26.61%
4 Years
20.26%
0%
20.26%
5 Years
52.43%
0%
52.43%
Tibet Weixinkang Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.22%
EBIT Growth (5y)
53.44%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.91
Tax Ratio
10.80%
Dividend Payout Ratio
60.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
32.01%
ROE (avg)
12.94%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
3.36
EV to EBIT
17.05
EV to EBITDA
13.92
EV to Capital Employed
8.58
EV to Sales
3.21
PEG Ratio
1.71
Dividend Yield
2.97%
ROCE (Latest)
50.31%
ROE (Latest)
17.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
273.10
287.50
-5.01%
Operating Profit (PBDIT) excl Other Income
51.90
81.90
-36.63%
Interest
0.10
0.00
Exceptional Items
10.50
13.20
-20.45%
Consolidate Net Profit
36.40
98.20
-62.93%
Operating Profit Margin (Excl OI)
190.00%
241.60%
-5.16%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -5.01% vs -1.64% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -62.93% vs 16.21% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,286.90
1,308.60
-1.66%
Operating Profit (PBDIT) excl Other Income
281.10
193.60
45.20%
Interest
0.30
0.40
-25.00%
Exceptional Items
-19.20
11.60
-265.52%
Consolidate Net Profit
246.20
214.00
15.05%
Operating Profit Margin (Excl OI)
176.00%
109.50%
6.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.66% vs -5.40% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.05% vs 20.90% in Dec 2023
About Tibet Weixinkang Medicine Co., Ltd. 
Tibet Weixinkang Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






